Diffuse large B-cell lymphoma is highly heterogeneous and is diagnosed according to the 2016 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. The decision of treatment should be upon age, International Prognostic Index score and the tolerability of chemotherapy. High-dose chemotherapy and autologous stem cell transplantation is the standard care for relapsed, chemotherapy sensitive patients. Clinical trials are recommended in specific conditions.
In April 2025, the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO) formally issued the CSCO Guidelines for Breast Cancer Diagnosis and Treatment (2025 Edition). These guidelines, building upon the 2024 edition, adhere to a stringent update protocol that incorporates evidence-based medical research, drug accessibility, and expert consensus, thereby ensuring scientific rigor while improving clinical applicability. This article systematically examines the principal revisions pertaining to the diagnosis and treatment of human epidermal growth factor receptor 2-positive breast cancer in the latest edition of the guidelines. We provide a comprehensive analysis, integrating the most recent international evidence-based medical findings, with the objective of offering a standardized reference for clinical decision-making.